secwatch.observer — SEC 8-K summary
======================================

Issuer:     TREACE MEDICAL CONCEPTS, INC. (TMCI)
CIK:        0001630627
Form:       8-K
Filed at:   2021-11-04T23:59:59+00:00
Accession:  0001564590-21-054483
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Treace Medical Q3 revenue $21.6M (+52% YoY); net loss ($6.4M); FY21 guidance reaffirmed $90-95M
--------------------------------------------------------------------------------

- Revenue $21.6M, up 52% YoY from $14.3M; gross margin 80.4% (+80 bps).
- Net loss ($6.4M) or ($0.12) per share vs ($2.8M) or ($0.08) in Q3 2020.
- Full-year 2021 revenue guidance reaffirmed at $90M-$95M (57-65% growth).
- Cash $109.5M; launched Adductoplasty System; appointed two new board members.
- ALIGN3D study showed 0.9% recurrence at 12 months; first Mini3D patient treated.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1630627/000156459021054483/0001564590-21-054483-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1630627/000156459021054483/tmci-8k_20211104.htm
  HTML page:      https://secwatch.observer/filing/0001564590-21-054483

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer